Edison Releases Report on The Biotech Growth Trust (BIOG)

Edison Investment Research has published a report on The Biotech Growth Trust (BIOG), managed by Geoff Hsu and Josh Golomb of OrbiMed. The trust aims for long-term capital growth by investing in biotech stocks, focusing on smaller, emerging companies. Since early 2021, the trust has encountered challenges amid an industry-wide downturn. However, the managers believe there is a disconnect between current stock valuations and the promising fundamentals of the biotech sector. They highlight the sector's peak innovation, a supportive regulatory climate, and potential M&A activity as pharmaceuticals seek to strengthen their pipelines.